Bleeding on DOACs (Direct Oral Anticoagulants)Hematology
Symptoms
Bleeding in a patient on a DOAC: apixaban, edoxaban, rivaroxaban (direct factor Xa inhibitors) or dabigatran (direct thrombin inhibitor). Indications: stroke prevention in non-valvular AF, treatment/prevention of VTE (rivaroxaban also ACS)
Mild bleeding: minor, no haemodynamic compromise
Moderate/severe bleeding: fall in Hb β₯20 g/L, transfusion of β₯2 units red cells, or symptomatic bleeding in a critical area/organ (intraocular, intra-articular, intraspinal, pericardial, intramuscular with compartment syndrome)
Life-threatening bleeding: symptomatic intracranial bleed, fall in Hb β₯50 g/L, transfusion of β₯4 units, hypotension requiring inotropes, or bleeding requiring surgical intervention
Risk of accumulation: renal impairment (esp. dabigatran), elderly (rivaroxaban), overdose
Investigations
Record the time of the last DOAC dose
Bloods: FBC, group & save, renal profile (U&E) and calcium, coagulation screen (aPTT, PT, thrombin time) and fibrinogen
Half-lives: apixaban ~12h; edoxaban 10β14h; dabigatran 12β14h (longer in renal impairment); rivaroxaban 5β9h (longer in elderly)
Coagulation tests are not standardised to quantify DOAC effect β serial results only suggest clearance
aPTT: prolonged at therapeutic dabigatran levels (but normal does not fully exclude effect); Xa inhibitors prolong aPTT only at supratherapeutic levels β a normal aPTT does not exclude significant levels
Thrombin time: a normal TT effectively excludes dabigatran (discuss with laboratory before requesting)
Anti-Xa (chromogenic) assay: useful for apixaban/edoxaban/rivaroxaban β a normal level indicates minimal anticoagulant activity
PT/INR: unreliable β normal does not exclude DOAC effect; may be raised with edoxaban/rivaroxaban, weakly affected by apixaban, not expected to rise with therapeutic dabigatran
Treatment
First steps (all patients): stop the DOAC; resuscitate (ABC) with oxygen and haemodynamic support; activate massive haemorrhage protocol if major bleeding; local haemostasis β mechanical compression, wound packing or surgical intervention
Fluids: replace fluid to maintain good urine output/diuresis, which aids renal clearance of the DOAC
Activated charcoal: consider Activated charcoal 100g PO/NG if last dose within 2h (up to 6h for apixaban, 8h for rivaroxaban), especially in overdose
Antiplatelet effect: consider platelet transfusion if thrombocytopenic or on long-acting antiplatelets (aspirin, clopidogrel, prasugrel, ticlopidine)
Mild bleeding: delay the next dose or discontinue DOAC if appropriate; local measures
Moderate/severe bleeding: fluid replacement plus blood-product support to keep Hb >80 g/L, platelets >75 Γ10βΉ/L, fibrinogen >1.0 g/L, aPTT <1.5Γ normal; consider Tranexamic acid 1g IV bolus over 10 min, then 1g over 8 hours
Life-threatening β dabigatran:Idarucizumab 5g IV (2 Γ 2.5g/50mL) as two consecutive infusions over 5β10 min each, or as a bolus β first-line. A second 5g dose may be considered if clinically relevant bleeding recurs with prolonged clotting times, or re-bleeding would be life-threatening with prolonged clotting times (dabigatran levels can rebound up to 24h)
Life-threatening β apixaban, edoxaban, rivaroxaban: consider Prothrombin complex concentrate (e.g. Beriplex) 50 units (factor X)/kg = 2 mL/kg, max 5000 units (dose by weight up to 100kg; >100kg see product information/haematologist); infuse at β€3 units/kg/min, max 210 units/min (~8 mL/min). Evidence limited; PCC is pro-thrombotic
Specific Xa-inhibitor antidote (literature, where available/licensed):Andexanet alfa β low dose 400mg IV bolus then 4mg/min for up to 120 min (apixaban β€5mg, rivaroxaban β€10mg, or last dose >8h ago); high dose 800mg IV bolus then 8mg/min for up to 120 min (higher doses or unknown/within 8h). Check local availability and product information
Not useful: protamine sulphate and vitamin K do not reverse DOACs β do not use
Dialysis: apixaban, edoxaban and rivaroxaban are highly protein-bound and not expected to be dialysable; dabigatran can be removed by haemodialysis/haemoperfusion (limited evidence for charcoal filtration)
After bleeding controlled: review ongoing need for anticoagulation; weigh risks/benefits and contraindications to restarting; check renal function; consider restarting at a lower licensed dose if appropriate; report the bleeding event through your drug-safety reporting scheme